brimonidine tartrate has been researched along with Glaucoma in 185 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 22 (11.89) | 18.2507 |
| 2000's | 77 (41.62) | 29.6817 |
| 2010's | 63 (34.05) | 24.3611 |
| 2020's | 23 (12.43) | 2.80 |
| Authors | Studies |
|---|---|
| Elmi Sadr, N; Paknazar, F; Saber, E | 1 |
| Çakmak, K; Erbil, H; Korkmaz, Ş; Mesci, C | 1 |
| Bachmann, LM; Bittner, M; Bochmann, F; Enz, TJ; Schmid, MK; Thiel, MA; Tribble, JR; Williams, PA | 1 |
| Hong, J; Huang, C; Sun, J; Sun, X; Xu, J; Zhang, Z; Zhao, Y | 1 |
| Li, H; Xu, Y | 1 |
| Abdel Azim, EA; El Hoffy, NM; Elkheshen, SA; Fouly, MA; Hathout, RM | 1 |
| Chambers, A; Cumpston, KL; Kershner, E; Tobarran, N; Wills, BK | 1 |
| Köse, HC; Tekeli, O | 1 |
| Bigdeli, A; Feghhi, M; Makhmalzadeh, BS; SoleimaniBiatiani, E | 1 |
| Aoki, R; Dote, S; Kimura, Y; Nagata, Y; Nakakura, S; Oogi, S; Shiraishi, M; Terao, E; Ueda, K | 1 |
| Kim, KE; Kim, Y; Lee, CK; Rho, S; Shin, J | 1 |
| Alkahtani, HM; Alomar, AM; Bakheit, AH; Darwish, H | 1 |
| Celikay, O; Eraslan, N | 1 |
| Boccaccini, A; Bocedi, A; Carnevale, C; Cavaterra, D; Graziani, G; Lacal, PM; Manni, G; Marini, S; Sbardella, D; Tanga, L; Tundo, GR | 1 |
| Kurysheva, NI | 2 |
| Wu, J; Zhang, T; Zhou, X | 1 |
| Sedlak, L; Wojnar, W; Wyględowska-Promieńska, D; Zych, M | 1 |
| Kawamura, A; Kozai, S; Kunikane, E; Kurata, M; Shigemi, W; Shinno, K; Suzuki, G | 1 |
| Aiello, F; Bagetta, G; Cesareo, M; Corasaniti, MT; Nucci, C; Scuteri, D; Tonin, P | 1 |
| Cardiel, MJ; Fraile, JM; Garcia-Martin, E; Luna, C; Martinez-Rincon, T; Mayoral, JA; Mendez-Martinez, S; Polo, V; Ramirez, T; Rodrigo, MJ; Ruberte, J; Subias, M; Vispe, E | 1 |
| Navarro-Triviño, FJ; Ruiz-Villaverde, R | 1 |
| Bartz-Schmidt, KU; de Vries, JW; Frößl, K; Gruszka, A; Herrmann, A; Hurst, J; Löscher, M; Schnichels, S; Spitzer, MS; Ullah, S | 1 |
| Akaray, İ; Çınar, AC; Çınar, AK; Güçlü, H; Gürlü, V; Sakallıoğlu, AK; Şambel Aykutlu, M | 1 |
| Chen, LC; Chuang, LH; Huang, SM; Lin, YH; Su, WW | 1 |
| Chen, HS; Cheng, YC; Lee, YS; Shen, SC; Shie, SS; Su, WW; Wu, WC; Yeh, PH | 1 |
| Comet, A; Courjaret, JC; Denis, D; Donnadieu, B; Gascon, P; Matonti, F | 1 |
| Goldberg, I; Lusthaus, JA | 1 |
| Chiboub, O; De Agustino Rodríguez, J; López-Arencibia, A; Lorenzo-Morales, J; Piñero, JE; Reyes-Batlle, M; Rocha-Cabrera, P; Sifaoui, I; Valladares, B; Wagner, C | 1 |
| Holopainen, JM; Pisella, PJ; Rantamäki, AH; Robciuc, A; Ruokonen, SK; Wiedmer, SK; Witos, J | 1 |
| Baker, MM; Belal, TS | 1 |
| Ikeda, Y; Kato, H; Kinoshita, S; Maruyama, Y; Mori, K; Sotozono, C; Ueno, M; Yokoi, N | 1 |
| Ciftci, F; Eyuboglu, S; Gumusel, A; Guzel, E; Marangoz, D; Seckin, I; Yalvac, I; Yilmaz, B | 1 |
| Barse, RK; Kokare, CR; Sharma, JP; Sharma, PK; Tagalpallewar, AA | 1 |
| Bro, T; Lindén, C | 1 |
| Choy, YB; Ha, A; Huh, BK; Kim, SN; Kim, YK; Ko, SA; Lee, SH; Park, CG; Park, KH; Park, YH | 1 |
| Newton, MJ | 1 |
| Chen, JL; Dikopf, MS; Oh, DJ; Vajaranant, TS | 1 |
| Kim, HY; Kim, MS; Lee, JH; Lee, SK; Lee, UH; Suh, JH | 1 |
| Barwal, I; Dada, T; Kumar, R; Yadav, SC | 1 |
| El Abass, SA; Elmansi, HM; Ibrahim, FA | 1 |
| Emad Eldeeb, A; Ghorab, M; Salah, S | 1 |
| Hwang, HB; Kim, SY; Ohn, K | 1 |
| Abd-Elgawad, AE; Ibrahim, MM; Jablonski, MM; Soliman, OA | 1 |
| Iotova, V; Kiryazov, K; Stefova, M | 1 |
| Fukuchi, T | 1 |
| Cherukury, M; Durairaj, C; Shen, J | 1 |
| Hallböök, F; Harun-Or-Rashid, M; Lindqvist, N | 1 |
| Harada, C; Harada, T; Kimura, A; Mitamura, Y; Namekata, K; Semba, K | 1 |
| Chew, SK; Goldberg, I; Skalicky, SE | 1 |
| Guzman-Aranguez, A; Loma, P; Perez de Lara, MJ; Pintor, J | 1 |
| Arimura, S; Inatani, M; Kozai, S; Matsumura, T; Takamura, Y; Takihara, Y; Tomomatsu, T; Yokota, S | 1 |
| Jung, KI; Kim, JH; Park, CK | 1 |
| Choi, SY; Choy, YB; Chung, YJ; Jung, YE; Kim, MH; Kim, MJ; Kim, YK; Lee, SH; Lee, WS; Park, CG; Park, KH; Park, M | 1 |
| Chiang, B; Doty, AC; Grossniklaus, HE; Kim, YC; Prausnitz, MR; Schwendeman, SP | 1 |
| Bachiller Cacho, MP; de Frutos-Lezaun, M; Egía Zurutuza, A; Irastorza Larburu, MB; Martínez-Soroa, I; Ostra Beldarrain, M | 1 |
| Cunningham, ET; Garg, SJ; London, NJ; Moorthy, R; Zierhut, M | 1 |
| Cho, IS; Cho, MO; Choy, YB; Huh, BK; Huh, KM; Kang, SW; Khatun, Z; Li, Z; Park, CG | 1 |
| Bornscheuer, C; Hopf, S; Pfeiffer, N; Prokosch, V | 1 |
| Mohamed, ST; Pek, YS; Wu, H; Ying, JY | 1 |
| Inada, K; Kawamura, A; Kozai, S; Kurokawa, K; Shinno, K; Tokushige, H | 1 |
| Dai, Z; Huang, T; Lei, Y; Liu, X; Sun, J; Sun, X; Wu, J; Xu, ZP | 1 |
| Batoosingh, AL; Cantor, LB; Liu, CC; Safyan, E | 1 |
| Agey, P; Dong, CJ; Guo, Y; Hare, WA; Wheeler, L | 1 |
| Motolko, MA | 1 |
| Batiste, C; Fudemberg, SJ; Katz, LJ | 1 |
| Călugăru, D; Călugăru, M | 1 |
| Delgado-Ortega, L; Díaz-Cerezo, S; Pinazo-Durán, MD; Soto-Alvarez, J; Vinuesa-Silva, I; Vinuesa-Silva, JM | 1 |
| Mint, JO; Poling, TR; Schultz, CL | 1 |
| Karczewicz, D; Kuprjanowicz, L | 1 |
| Cheng, JW; Li, Y; Wei, RL | 1 |
| Augustinus, B; De Smet, MD; Hondeghem, K | 1 |
| Earl, M; Nguyen, QH | 1 |
| Campos, JG; Díaz, F; Moreno, M; Pérez de Vargas, I; Vidal, L; Villena, A | 1 |
| Katz, LJ; Razeghinejad, MR; Sawchyn, AK | 1 |
| Montgomery, DM; Rahman, MQ; Ramaesh, K | 1 |
| Adams, BH; Broderick, DF; Menke, DM; Runyan, BR; Shetty, RK; Tun, HW | 1 |
| Dermon, C; Panagis, L; Prokosch, V; Thanos, S; Volk, GF | 1 |
| Alldredge, B; Gerhardt, G; Halverson, K; Pensyl, D; Qualls, C; Sullivan-Mee, M | 1 |
| Artunay, O; Bahcecioglu, H; Rasier, R; Sengul, A; Unal, M; Yuzbasioglu, E | 1 |
| Bernstein, P; Caprioli, J; Schiffman, RM; Spaeth, GL | 1 |
| Hendrikse, F; Peeters, A; Prins, MH; Schouten, JS; Webers, CA | 1 |
| Abdlseaed, AA; Abeysinghe, SS; Kelly, S; Montgomery, DM; Rahman, MQ; Roskell, NS; Shannon, PR | 1 |
| Crichton, A; Fielden, M; Hall, R; Kherani, A; Kherani, F | 1 |
| Maiti, S; Mondol, R; Paul, S; Ray, S; Sa, B | 1 |
| Bhagav, P; Chandran, S; Upadhyay, H | 1 |
| Arriola-Villalobos, P; Díaz-Valle, D; Garcia-Gil-de-Bernabé, J; Iglesias-Lodares, I | 1 |
| Holden, CA; Jadhav, G; Kadam, R; Kompella, UB; Thakur, A; Tyagi, P; Yang, H | 1 |
| Aburahma, MH; Mahmoud, AA | 1 |
| Geethalakshmi, A; Jha, SK; Karki, R; Nikunj, B; Venkatesh, DP | 1 |
| Cottingham, AJ; Hollander, DA; Katz, LJ; Rauchman, SH; Schiffman, RM; Simmons, ST; Williams, JM | 1 |
| Congdon, NG; Friedman, DS; Gilbert, D; Goggins, W; Kader, MA; Krishnadas, R; Quigley, HA; Ramakrishnan, R; Tielsch, J | 1 |
| Chang, TH; Chen, FA; Chien, ST; Horng, CT; Kao, WT; Tsai, MK; Tsai, ML | 1 |
| Inoue, Y; Kaneko, E; Minagawa, Y; Wada, T | 1 |
| Méndez-Hernández, C | 1 |
| Carrasco, MA; Schlaen, BA; Zárate, JO | 1 |
| Holló, G; Kóthy, P | 1 |
| Cho, J; Mullins, CD; Shaya, FT; Wong, W | 1 |
| Baudouin, C; Titouamane, S | 1 |
| Naskar, R; Quinto, K; Schuettauf, F; Zurakowski, D | 1 |
| Phelan, P | 1 |
| Cheng, CY; Chou, JC; Hsu, WM; Ko, YC; Liu, CJ; Liu, JH | 1 |
| Coracas, A; Eckhardt, C; Sauer, S | 1 |
| Kim, P; Lertsumikul, S | 1 |
| Batoosingh, A; Felix, C; Mundorf, T; Whitcup, S; Williams, R | 1 |
| Koren, G; Levin, AV; Mungan, NK; Nischal, KK; Wilson, TW | 1 |
| Fong, JC; Hong, SJ; Wang, HZ; Wu, KY | 1 |
| Lai, R; Wheeler, L; WoldeMussie, E | 1 |
| Chen, MJ; Chou, JC; Hsu, WM; Liu, JH | 1 |
| Mozaffari, E; Reardon, G; Schwartz, GF | 1 |
| Assalian, A; Castilloux, AM; Houde, M; LeLorier, J; Tingey, D | 1 |
| Bowman, RJ; Cope, J; Nischal, KK | 1 |
| Bonini, S; Bucci, MG; Centofanti, M; Manni, G; Oddone, F; Parravano, M; Sacchetti, M | 1 |
| Cunliffe, I; García-Sánchez, J; Landry, J; Pajic, B; Rouland, JF; Spiegel, D; Traverso, C | 1 |
| Becker, HI; Diamant, JI; Walton, RC; Zegans, ME | 1 |
| McKay, IC; Montgomery, DM; Morris, D; Osborne, SA | 1 |
| Appaswamy, S; Bhatt, R; Desai, A; Fitt, A; Sandramouli, S; Whittaker, KW | 1 |
| Ignat, F | 1 |
| Cheng, CY; Hsu, WM; Ko, YC; Liu, CJ | 1 |
| Burnier, MN; Saheb, NE; Saraiva, VS; Solari, HP; Ventura, MP; Vianna, RN | 1 |
| Cheetham, JK; Chou, C; Craven, ER; Schiffman, R; Walters, TR; Williams, R | 1 |
| Al-Jadaan, I; Al-Omran, M; Al-Shahwan, S; Al-Torbak, AA; Edward, DP; Turkmani, S | 1 |
| Susanna, R; Vaidergorn, PG | 1 |
| Márquez-de-Aracena, R; Montero-de-Espinosa, I; Morales, C | 1 |
| Avila, MP; Magacho, L; Queiroz, CF; Reis, R; Santos, LC | 1 |
| Daubert, GP | 1 |
| Jurisić, D; Lacmnovic-Loncar, V; Mandić, Z; Petric, I; Sesar, A; Sesar, I; Tomić, Z | 1 |
| Baudouin, C; Bron, AM; Creuzot-Garcher, C; Lizard, G; Malvitte, L; Montange, T; Vejux, A | 1 |
| Craig, JC; Fung, AT; Healey, PR; Jones, MP; McCluskey, PJ; Reid, SE | 1 |
| Fiscella, R | 1 |
| Feldman, RM | 1 |
| Goñi, FJ | 1 |
| Greenfield, DS; Krupin, T; Liebmann, JM; Ritch, R | 1 |
| Heimann, K; Hoernchen, H; Merz, U; Peschgens, T; Wenzl, T | 1 |
| Craven, ER; Katz, LJ; Simmons, ST | 1 |
| Barnes, D; Ducruet, T; Foerster, V; Hodge, WG; Lachaine, J; Morrison, A; Murray, C; Steffensen, I | 1 |
| Day, DG; Hollander, DA | 1 |
| Craig, JC; Fung, A; Liew, G; Loon, SC; Reid, SE | 1 |
| Serle, JB | 1 |
| Barnebey, HS; Chen, KS; Cinotti, DJ; Coleman, AL; Hersh, SB; Lewis, RA; Morrison, JC; Robin, AL; Walt, J; Zimmerman, TJ | 1 |
| Clevenger, CE; David, R; Henry, JC; Passo, MS; Perell, HF; Siegel, LI; Spaeth, GL; Stamper, RL; Stiles, MC; Walt, JG | 1 |
| Burke, J; Schwartz, M | 1 |
| Hill, R | 1 |
| Greenfield, DS; Liebmann, JM; Ritch, R | 1 |
| Crichton, AC | 1 |
| Gordon, RN; Greenfield, DS; Lama, P; Liebmann, JM; Ritch, R | 1 |
| Hoyng, PF; Rasker, MT | 1 |
| Mermoud, A | 1 |
| Edward, DP; Lark, KK; Pasha, AS; Yan, X | 1 |
| Gebhardt, DO | 1 |
| Burnstein, Y; Robin, AL | 1 |
| Assalian, A; Chevrier, RL; Duperré, J; Lesk, MR | 1 |
| Buys, YM; thoe Schwartzenberg, GW | 1 |
| Grote, A; Korsch, E; Seybold, M; Soditt, V | 1 |
| Barbe, ME; Carlsen, JO; Kwon, YH; Scott, WE; Zabriskie, NA | 1 |
| Hudgins, AC; Pruitt, CA; Sine, C; Stewart, WC | 1 |
| Ainsworth, J; Kulshrestha, M; Ng, S; Roff, E; Sedgwick, G | 1 |
| Carlsson, AM; Chauhan, BC; Leblanc, RP; Lee, AA | 1 |
| Apătăchioae, I; Chiseliţă, D | 1 |
| David, R; Melamed, S | 1 |
| Javitt, JC; Schiffman, RM | 1 |
| Gross, RL; Orengo-Nania, S; Williams, GC | 1 |
| Byles, DB; Frith, P; Salmon, JF | 1 |
| Detry-Morel, M; Dutrieux, C | 1 |
| Gagliuso, DJ; Podos, SM; Serle, JB; Wang, RF | 1 |
| Einarson, TR; Iskedjian, M; Kulin, NA; Tingey, D | 1 |
| Cantor, LB | 1 |
| Lagrèze, WA | 1 |
| Simmons, ST | 1 |
| Chalmers-Redman, RM; Mittag, TW; Podos, SM; Sud, A; Tatton, WG | 1 |
| Chew, P; Lat-Luna, M; Lim, BA; Tan, D; Xiong, X | 1 |
| Ahmed, FA; Chaudhary, P; Hegazy, K; Sharma, SC | 1 |
| Enyedi, LB; Freedman, SF | 1 |
| Maroteaux, I | 1 |
| Grehn, F | 1 |
| Azuara-Blanco, A; Bain, M; Bateman, DN; Clark, R; Forrest, J | 2 |
| Blondeau, P; Rousseau, JA | 1 |
| Katz, LJ | 1 |
| Maurin, JF; May, F; Renard, JP; Rigal-Sastourne, JC | 1 |
| Kasahara, N | 1 |
| Martone, JF; Mead, A; O'Connor, DJ | 1 |
28 review(s) available for brimonidine tartrate and Glaucoma
| Article | Year |
|---|---|
Novel frontiers in neuroprotective therapies in glaucoma: Molecular and clinical aspects.
Topics: Brimonidine Tartrate; Glaucoma; Humans; Neurodegenerative Diseases; Retina; Retinal Diseases; Retinal Ganglion Cells | 2023 |
Evidence on the neuroprotective properties of brimonidine in glaucoma.
Topics: Brimonidine Tartrate; Glaucoma; Humans; Intraocular Pressure; Quinoxalines; Randomized Controlled Trials as Topic; Vision Disorders; Visual Fields | 2020 |
[Brimonidine and acute anterior granulomatous uveitis: A case report and literature review].
Topics: Aged; Antihypertensive Agents; Brimonidine Tartrate; Female; Glaucoma; Humans; Uveitis, Anterior | 2017 |
Brimonidine and brinzolamide for treating glaucoma and ocular hypertension; a safety evaluation.
Topics: Administration, Ophthalmic; Animals; Antihypertensive Agents; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Drug Delivery Systems; Glaucoma; Humans; Ocular Hypertension; Sulfonamides; Thiazines | 2017 |
Brimonidine tartrate for the treatment of glaucoma.
Topics: Adrenergic alpha-Agonists; Brimonidine Tartrate; Glaucoma; Humans; Intraocular Pressure; Ocular Hypertension; Ophthalmic Solutions; Treatment Outcome | 2019 |
Brinzolamide plus brimonidine for the treatment of glaucoma: an update.
Topics: Adrenergic alpha-2 Receptor Agonists; Antihypertensive Agents; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Clinical Trials as Topic; Drug Combinations; Glaucoma; Humans; Intraocular Pressure; Quinoxalines; Sulfonamides; Thiazines | 2014 |
Efficacy, safety, and current applications of brimonidine.
Topics: Animals; Antihypertensive Agents; Brimonidine Tartrate; Drug Combinations; Glaucoma; Humans; Intraocular Pressure; Ocular Hypertension; Ophthalmic Solutions; Quinoxalines; Timolol; Treatment Outcome | 2008 |
[Fixed combinations of glaucoma medications].
Topics: Amides; Antihypertensive Agents; Bimatoprost; Brimonidine Tartrate; Cloprostenol; Drug Combinations; Drug Therapy, Combination; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Ophthalmic Solutions; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiophenes; Timolol; Travoprost; Treatment Outcome | 2008 |
[Development of conjunctival hyperemia with the use of a fixed combination of latanoprost/timolol: systematic review and meta-analysis of clinical trials].
Topics: Aged; Brimonidine Tartrate; Clinical Trials as Topic; Cloprostenol; Conjunctival Diseases; Cross-Over Studies; Drug Combinations; Drug Therapy, Combination; Glaucoma; Humans; Hyperemia; Latanoprost; Middle Aged; Ocular Hypertension; Odds Ratio; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiazines; Timolol; Travoprost | 2009 |
[Neuroprotection in glaucoma].
Topics: Betaxolol; Brimonidine Tartrate; Disease Progression; Glaucoma; Guanidines; Humans; Memantine; Neuroprotective Agents; Quinoxalines; Sulfonamides; Thiophenes | 2007 |
Systematic review of intraocular pressure-lowering effects of adjunctive medications added to latanoprost.
Topics: Aged; Antihypertensive Agents; Brimonidine Tartrate; Databases, Factual; Drug Therapy, Combination; Female; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Optic Nerve Diseases; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiazines; Thiophenes; Timolol | 2009 |
Fixed combinations of dorzolamide-timolol and brimonidine-timolol in the management of glaucoma.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Drug Combinations; Glaucoma; Humans; Intraocular Pressure; Patient Selection; Quinoxalines; Risk Assessment; Sulfonamides; Thiophenes; Timolol; Treatment Outcome | 2010 |
Brimonidine for glaucoma.
Topics: Adrenergic alpha-Agonists; Animals; Antihypertensive Agents; Brimonidine Tartrate; Glaucoma; Humans; Intraocular Pressure; Quinoxalines | 2010 |
Reappraising first-line treatment in glaucoma management.
Topics: Amides; Antihypertensive Agents; Bimatoprost; Brimonidine Tartrate; Cloprostenol; Dinoprost; Drug Therapy, Combination; Glaucoma; Humans; Latanoprost; Lipids; Prostaglandins; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiophenes; Travoprost | 2002 |
Role of alpha-2 agonists in neuroprotection.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Glaucoma; Humans; Neuroprotective Agents; Quinoxalines; Receptors, Adrenergic, alpha-2; Retinal Ganglion Cells | 2003 |
Meta-analysis of randomised controlled trials comparing latanoprost with brimonidine in the treatment of open-angle glaucoma, ocular hypertension or normal-tension glaucoma.
Topics: Administration, Topical; Aged; Antihypertensive Agents; Brimonidine Tartrate; Female; Glaucoma; Glaucoma, Open-Angle; Humans; Latanoprost; Male; Middle Aged; Ocular Hypertension; Prostaglandins F, Synthetic; Quinoxalines; Randomized Controlled Trials as Topic; Treatment Outcome | 2007 |
Efficacy and safety of brimonidine and dorzolamide for intraocular pressure lowering in glaucoma and ocular hypertension.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Clinical Trials as Topic; Drug Therapy, Combination; Female; Glaucoma; Humans; Intraocular Pressure; Male; Ocular Hypertension; Quinoxalines; Sulfonamides; Thiophenes; Treatment Outcome | 2007 |
The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review.
Topics: Adult; Aged; Antihypertensive Agents; Brimonidine Tartrate; Female; Glaucoma; Humans; Latanoprost; Male; Middle Aged; Prostaglandins F, Synthetic; Prostaglandins, Synthetic; Quinoxalines; Randomized Controlled Trials as Topic; Sulfonamides; Thiophenes; Treatment Outcome | 2008 |
Meta-analysis of randomized controlled trials comparing timolol with brimonidine in the treatment of glaucoma.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Brimonidine Tartrate; Glaucoma; Humans; Quinoxalines; Randomized Controlled Trials as Topic; Timolol; Treatment Outcome | 2008 |
Pharmacological advances in the treatment of glaucoma.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Clonidine; Ethacrynic Acid; Glaucoma; Humans; Latanoprost; Prostaglandins; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiophenes | 1994 |
Preclinical evaluation of brimonidine.
Topics: Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Cats; Cebus; Drug Evaluation, Preclinical; Glaucoma; Humans; Intraocular Pressure; Ocular Hypertension; Ophthalmic Solutions; Quinoxalines; Rabbits; Rats | 1996 |
Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Betaxolol; Brimonidine Tartrate; Clinical Trials as Topic; Dose-Response Relationship, Drug; Glaucoma; Humans; Intraocular Pressure; Ocular Hypertension; Ophthalmic Solutions; Quinoxalines; Timolol; Trabeculectomy | 1997 |
[Four new drugs for glaucoma: apraclonidine, brimonidine, dorzolamide and latanoprost].
Topics: Administration, Oral; Administration, Topical; Adrenergic alpha-Agonists; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Clonidine; Drug Therapy, Combination; Female; Glaucoma; Humans; Latanoprost; Male; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiophenes | 1998 |
[Alpha-2 adrenergic agonists in the treatment of glaucoma].
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Brimonidine Tartrate; Clonidine; Glaucoma; Humans; Intraocular Pressure; Quinoxalines | 1999 |
Meta-analysis of the effect of latanoprost and brimonidine on intraocular pressure in the treatment of glaucoma.
Topics: Brimonidine Tartrate; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Prostaglandins F, Synthetic; Quinoxalines | 2000 |
The evolving pharmacotherapeutic profile of brimonidine, an alpha 2-adrenergic agonist, after four years of continuous use.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Glaucoma; Humans; Neuroprotective Agents; Ocular Hypertension; Quinoxalines; Receptors, Adrenergic, alpha-2 | 2000 |
Maintaining mitochondrial membrane impermeability. an opportunity for new therapy in glaucoma?
Topics: Animals; Apoptosis; bcl-X Protein; Brimonidine Tartrate; Cell Membrane Permeability; Glaucoma; Humans; Intraocular Pressure; Mitochondria; Pargyline; Propylamines; Proto-Oncogene Proteins c-bcl-2; Quinoxalines; Retinal Ganglion Cells; Signal Transduction | 2001 |
[New medical treatments of glaucoma. New strategies?].
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Drug Therapy, Combination; Glaucoma; Humans; Prostaglandins; Quinoxalines | 2001 |
39 trial(s) available for brimonidine tartrate and Glaucoma
| Article | Year |
|---|---|
The prophylactic effect of betaxolol 0.5% versus brimonidine 0.2% on IOP elevation after Nd:YAG laser posterior capsulotomy.
Topics: Betaxolol; Brimonidine Tartrate; Capsule Opacification; Glaucoma; Humans; Intraocular Pressure; Lens Capsule, Crystalline; Ocular Hypertension; Posterior Capsulotomy; Postoperative Complications | 2022 |
Comparing the effects and safety of dorzolamide hydrochloride + timolol maleate versus brimonidine after neodymium-doped yttrium aluminium garnet laser capsulotomy posterior capsule opacification.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Capsule Opacification; Glaucoma; Humans; Intraocular Pressure; Lasers, Solid-State; Neodymium; Ocular Hypertension; Ophthalmic Solutions; Sulfonamides; Thiophenes; Timolol; Yttrium | 2022 |
Comparative Assessment of Retinal Blood Flow Velocity Changes Following Brimonidine and Brinzolamide Administration Using Retinal Function Imaging.
Topics: Adult; Blood Flow Velocity; Brimonidine Tartrate; Glaucoma; Humans; Ocular Hypertension; Sulfonamides; Thiazines; Young Adult | 2022 |
Comparisons of efficacy and safety between preserved and preservative-free brimonidine tartrate in glaucoma and ocular hypertension: a parallel-grouped, randomized trial.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Double-Blind Method; Glaucoma; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Ocular Hypertension; Ophthalmic Solutions; Preservatives, Pharmaceutical; Quinoxalines; Treatment Outcome | 2023 |
Influence of timolol, benzalkonium-preserved timolol, and benzalkonium-preserved brimonidine on oxidative stress biomarkers in the tear film.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic beta-Antagonists; Adult; Aged; Benzalkonium Compounds; Biomarkers; Brimonidine Tartrate; Catalase; Dry Eye Syndromes; Female; Glaucoma; Glutathione Peroxidase; Humans; Male; Middle Aged; Ophthalmic Solutions; Oxidative Stress; Preservatives, Pharmaceutical; Superoxide Dismutase; Tears; Timolol; Young Adult | 2020 |
Corneal epithelium and limbal region alterations due to glaucoma medications evaluated by anterior segment optic coherence tomography: a case-control study.
Topics: Aged; Antihypertensive Agents; Benzalkonium Compounds; Brimonidine Tartrate; Case-Control Studies; Epithelium, Corneal; Female; Glaucoma; Humans; Latanoprost; Limbus Corneae; Male; Middle Aged; Ophthalmic Solutions; Preservatives, Pharmaceutical; Single-Blind Method; Sulfonamides; Thiophenes; Timolol; Tomography, Optical Coherence | 2021 |
Vitreous and aqueous concentrations of brimonidine following topical application of brimonidine tartrate 0.1% ophthalmic solution in humans.
Topics: Administration, Topical; Adrenergic alpha-2 Receptor Agonists; Aged; Animals; Aqueous Humor; Brimonidine Tartrate; Chromatography, High Pressure Liquid; Epiretinal Membrane; Female; Glaucoma; Humans; Japan; Male; Middle Aged; Ophthalmic Solutions; Prospective Studies; Rats; Retinal Perforations; Tandem Mass Spectrometry; Vitrectomy; Vitreous Body | 2015 |
Brimonidine-purite 0.1% versus brimonidine-purite 0.15% twice daily in glaucoma or ocular hypertension: a 12-month randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Double-Blind Method; Drug Administration Schedule; Female; Glaucoma; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Quinoxalines; Treatment Outcome | 2008 |
Comparison of allergy rates in glaucoma patients receiving brimonidine 0.2% monotherapy versus fixed-combination brimonidine 0.2%-timolol 0.5% therapy.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Aged; Brimonidine Tartrate; Conjunctivitis, Allergic; Drug Therapy, Combination; Female; Glaucoma; Humans; Male; Middle Aged; Quinoxalines; Timolol | 2008 |
Fixed-combination brimonidine/timolol as adjunctive therapy to a prostaglandin analog: a 3-month, open-label, replacement study in glaucoma patients.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Drug Combinations; Drug Hypersensitivity; Drug Therapy, Combination; Female; Glaucoma; Humans; Intraocular Pressure; Male; Middle Aged; Prospective Studies; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiophenes; Time Factors; Timolol | 2009 |
Bimatoprost 0.03% versus brimonidine 0.2% in the prevention of intraocular pressure spike following neodymium:yttrium–aluminum–garnet laser posterior capsulotomy.
Topics: Aged; Aged, 80 and over; Amides; Antihypertensive Agents; Bimatoprost; Brimonidine Tartrate; Capsule Opacification; Cataract; Cloprostenol; Female; Glaucoma; Humans; Intraocular Pressure; Laser Therapy; Lasers, Solid-State; Male; Middle Aged; Neodymium; Ocular Hypertension; Ophthalmic Solutions; Posterior Capsule of the Lens; Quinoxalines; Tonometry, Ocular | 2010 |
Control of intraocular pressure and fluctuation with fixed-combination brimonidine-timolol versus brimonidine or timolol monotherapy.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Circadian Rhythm; Double-Blind Method; Drug Combinations; Glaucoma; Humans; Intraocular Pressure; Ocular Hypertension; Quinoxalines; Timolol; Tonometry, Ocular | 2011 |
Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Drug Combinations; Female; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Prostaglandins F, Synthetic; Quinoxalines; Time Factors; Timolol; Treatment Outcome | 2012 |
A study of initial therapy for glaucoma in southern India: India Glaucoma Outcomes and Treatment (INGOT) Study.
Topics: Aged; Antihypertensive Agents; Antimetabolites, Antineoplastic; Brimonidine Tartrate; Drug Combinations; Female; Fluorouracil; Glaucoma; Humans; India; Intraocular Pressure; Latanoprost; Lens Implantation, Intraocular; Male; Middle Aged; Phacoemulsification; Prospective Studies; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Surveys and Questionnaires; Thiophenes; Timolol; Tonometry, Ocular; Trabeculectomy; Visual Acuity | 2012 |
Does glaucoma medication influence the diameter of the retinal arteriole in the human eye? (A pilot study using the retinal vessel analyser).
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Arterioles; Betaxolol; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Glaucoma; Humans; Latanoprost; Middle Aged; Ophthalmology; Pilot Projects; Prostaglandins F, Synthetic; Quinoxalines; Retinal Artery; Sulfonamides; Thiazines; Timolol | 2001 |
[Use of brimonidine 0.2% in treatment of glaucoma or ocular hypertony after poorly tolerated beta-blocker treatment].
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Appetite; Brimonidine Tartrate; Glaucoma; Humans; Intraocular Pressure; Ocular Hypertension; Patient Satisfaction; Quality of Life; Quinoxalines; Surveys and Questionnaires; Treatment Failure; Treatment Outcome | 2002 |
Effect of latanoprost 0.005% and brimonidine tartrate 0.2% on pulsatile ocular blood flow in normal tension glaucoma.
Topics: Adult; Aged; Antihypertensive Agents; Brimonidine Tartrate; Cross-Over Studies; Eye; Female; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Prostaglandins F, Synthetic; Pulsatile Flow; Quinoxalines | 2002 |
A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension.
Topics: Adrenergic alpha-Agonists; Brimonidine Tartrate; Conjunctiva; Conjunctivitis, Allergic; Dose-Response Relationship, Drug; Double-Blind Method; Glaucoma; Humans; Hyperemia; Intraocular Pressure; Ocular Hypertension; Quinoxalines; Severity of Illness Index | 2003 |
The efficacy and safety of brimonidine 0.2% compared with timolol 0.5% in glaucoma: a randomized clinical trial on Taiwanese patients.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Brimonidine Tartrate; Female; Glaucoma; Heart; Humans; Male; Quinoxalines; Retrospective Studies; Timolol | 2003 |
A comparison of the fixed combination of latanoprost and timolol with the unfixed combination of brimonidine and timolol in patients with elevated intraocular pressure. A six month, evaluator masked, multicentre study in Europe.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Drug Therapy, Combination; Europe; Female; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Ocular Hypertension; Prostaglandins F, Synthetic; Quinoxalines; Timolol; Treatment Outcome | 2004 |
Diurnal intraocular pressure and blood pressure with two dosing regimens of brimonidine in normal tension glaucoma.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Blood Pressure; Brimonidine Tartrate; Circadian Rhythm; Drug Administration Schedule; Female; Glaucoma; Humans; Intraocular Pressure; Male; Middle Aged; Quinoxalines | 2004 |
Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Brimonidine Tartrate; Double-Blind Method; Drug Combinations; Female; Glaucoma; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Quinoxalines; Timolol; Treatment Outcome | 2005 |
A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Aged; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Cloprostenol; Double-Blind Method; Drug Therapy, Combination; Female; Glaucoma; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Prospective Studies; Quinoxalines; Sulfonamides; Thiazines; Timolol; Travoprost | 2006 |
Visual field and intraocular pressure asymmetry in the low-pressure glaucoma treatment study.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Aging; Brimonidine Tartrate; Circadian Rhythm; Double-Blind Method; Female; Glaucoma; Humans; Intraocular Pressure; Male; Middle Aged; Quinoxalines; Timolol; Visual Fields | 2007 |
Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension.
Topics: Adult; Aged; Analysis of Variance; Brimonidine Tartrate; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Male; Maximum Tolerated Dose; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Organization and Administration; Probability; Prostaglandins F, Synthetic; Quinoxalines; Risk Assessment; Severity of Illness Index; Single-Blind Method; Sulfonamides; Thiazines; Tonometry, Ocular; Treatment Outcome | 2008 |
The efficacy of brimonidine in decreasing elevations in intraocular pressure after laser trabeculoplasty.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Brimonidine Tartrate; Double-Blind Method; Drug Tolerance; Glaucoma; Humans; Intraocular Pressure; Laser Therapy; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Pharmaceutical Vehicles; Quinoxalines; Trabeculectomy | 1993 |
Brimonidine in the prevention of intraocular pressure elevation following argon laser trabeculoplasty.
Topics: Adrenergic alpha-Agonists; Adult; Antihypertensive Agents; Brimonidine Tartrate; Double-Blind Method; Glaucoma; Humans; Intraocular Pressure; Laser Therapy; Ocular Hypertension; Ophthalmic Solutions; Quinoxalines; Trabeculectomy | 1993 |
Lack of cross-reactive allergic response to brimonidine in patients with known apraclonidine allergy.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Clonidine; Cross Reactions; Drug Hypersensitivity; Eye Diseases; Follow-Up Studies; Glaucoma; Humans; Middle Aged; Quinoxalines; Time Factors | 1998 |
Pressure or progression?
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Brimonidine Tartrate; Disease Progression; Glaucoma; Humans; Intraocular Pressure; Ocular Hypertension; Quinoxalines; Timolol; Visual Fields | 1999 |
Apraclonidine 0.5% versus brimonidine 0.2% for the control of intraocular pressure elevation following anterior segment laser procedures.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Anterior Eye Segment; Brimonidine Tartrate; Chronic Disease; Clonidine; Female; Glaucoma; Humans; Intraocular Pressure; Laser Therapy; Male; Middle Aged; Observer Variation; Ocular Hypertension; Ophthalmic Solutions; Prospective Studies; Quinoxalines; Trabeculectomy; Treatment Outcome | 1999 |
Efficacy of brimonidine 0.2% as adjunctive therapy for patients with glaucoma inadequately controlled with otherwise maximal medical therapy.
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Brimonidine Tartrate; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Glaucoma; Humans; Intraocular Pressure; Male; Middle Aged; Ophthalmic Solutions; Quinoxalines; Retrospective Studies; Safety; Treatment Outcome | 1999 |
Daily cost of newer glaucoma agents.
Topics: Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Gels; Glaucoma; Humans; Latanoprost; Prostaglandins F, Synthetic; Quinoxalines; Solutions; Sulfonamides; Thiophenes; Timolol | 1999 |
The effect of brimonidine tartrate on retinal blood flow in patients with ocular hypertension [corrected].
Topics: Administration, Topical; Adrenergic alpha-Agonists; Blood Flow Velocity; Brimonidine Tartrate; Disease Progression; Double-Blind Method; Female; Glaucoma; Humans; Intraocular Pressure; Laser-Doppler Flowmetry; Male; Middle Aged; Ocular Hypertension; Quinoxalines; Retinal Vessels; Visual Fields | 1999 |
Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Brimonidine Study Group II.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Blood Pressure; Brimonidine Tartrate; Double-Blind Method; Female; Glaucoma; Heart Rate; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Quinoxalines; Timolol; Vision Tests | 2000 |
Clinical success and quality of life with brimonidine 0.2% or timolol 0.5% used twice daily in glaucoma or ocular t hypertension: a randomized clinical trial. Brimonidine Outcomes Study Group I.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Blood Pressure; Brimonidine Tartrate; Double-Blind Method; Drug Administration Schedule; Drug Evaluation; Female; Glaucoma; Heart Rate; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Prospective Studies; Quality of Life; Quinoxalines; Safety; Surveys and Questionnaires; Timolol; Treatment Outcome | 2000 |
[Treatment of glaucoma with brimonidine (Alphagan 0.2%)].
Topics: Adolescent; Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Brimonidine Tartrate; Child; Drug Therapy, Combination; Female; Glaucoma; Humans; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Quinoxalines | 2000 |
Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Brimonidine Tartrate; Cross-Over Studies; Down-Regulation; Female; Glaucoma; Humans; Immunologic Factors; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Quality of Life; Quinoxalines; Sulfonamides; Thiophenes | 2001 |
Safety and efficacy of brimonidine in children with glaucoma.
Topics: Adolescent; Adrenergic alpha-Agonists; Antihypertensive Agents; Brimonidine Tartrate; Central Nervous System Diseases; Child; Child, Preschool; Female; Glaucoma; Humans; Intraocular Pressure; Male; Ophthalmic Solutions; Quinoxalines; Safety; Tonometry, Ocular | 2001 |
Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Conjunctivitis, Allergic; Double-Blind Method; Drug Evaluation; Female; Glaucoma; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Patient Satisfaction; Preservatives, Pharmaceutical; Quality of Life; Quinoxalines; Safety | 2002 |
118 other study(ies) available for brimonidine tartrate and Glaucoma
| Article | Year |
|---|---|
Sustained release of brimonidine from BRI@SR@TPU implant for treatment of glaucoma.
Topics: Animals; Antihypertensive Agents; Brimonidine Tartrate; Cell Line; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Implants; Drug Liberation; Glaucoma; Humans; Intraocular Pressure; Ophthalmic Solutions; Rabbits; Random Allocation; Silicones | 2022 |
In vitro and in vivo evaluation of brimonidine loaded silica nanoparticles-laden silicone contact lenses to manage glaucoma.
Topics: Animals; Brimonidine Tartrate; Contact Lenses; Drug Delivery Systems; Glaucoma; Humans; Nanoparticles; Ophthalmic Solutions; Rabbits; Silicon Dioxide; Silicones | 2022 |
Augmented in vitro and in vivo Profiles of Brimonidine Tartrate Using Gelatinized-Core Liposomes.
Topics: Animals; Brimonidine Tartrate; Glaucoma; Intraocular Pressure; Liposomes; Plasticizers; Rabbits | 2022 |
Systemic toxicity from subcutaneous brimonidine injection successfully treated with naloxone.
Topics: Adrenergic alpha-Agonists; Aged; Analgesics, Opioid; Bradycardia; Brimonidine Tartrate; Drug Overdose; Female; Glaucoma; Humans; Hypotension; Infant; Injections, Subcutaneous; Lethargy; Naloxone; Ophthalmic Solutions; Quinoxalines | 2022 |
Evaluation of the Use of Brinzolamide-Brimonidine Fixed Combination in Maximum Medical Therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Drug Combinations; Female; Glaucoma; Glaucoma, Open-Angle; Humans; Male; Middle Aged; Ocular Hypertension; Retrospective Studies; Sulfonamides; Thiazines; Young Adult | 2022 |
Cationic liposomes as promising vehicles for timolol/brimonidine combination ocular delivery in glaucoma: formulation development and in vitro/in vivo evaluation.
Topics: Animals; Antihypertensive Agents; Brimonidine Tartrate; Glaucoma; Intraocular Pressure; Liposomes; Polymers; Quinoxalines; Rabbits; Timolol | 2023 |
Efficacy and safety of a fixed combination of 1% brinzolamide and 0.1% brimonidine as treatment for glaucoma: a retrospective study focusing on the number of ingredients.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Drug Combinations; Glaucoma; Glaucoma, Open-Angle; Humans; Ocular Hypertension; Retrospective Studies | 2022 |
Brimonidine.
Topics: Adrenergic alpha-Agonists; Antihypertensive Agents; Brimonidine Tartrate; Glaucoma; Glaucoma, Open-Angle; Humans; Ophthalmic Solutions; Quinoxalines | 2023 |
Assessment of corneal sublayer thickness changes in glaucoma patients using optical coherence tomography and correlation of epithelial layer thinning with dry eye monitoring.
Topics: Brimonidine Tartrate; Brimonidine Tartrate, Timolol Maleate Drug Combination; Dry Eye Syndromes; Glaucoma; Glaucoma, Open-Angle; Humans; Longitudinal Studies; Photochemotherapy; Photosensitizing Agents; Timolol; Tomography, Optical Coherence | 2023 |
[Selective α2 agonists in the treatment of glaucoma: neuroprotective properties and impact on ocular blood flow].
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Brimonidine Tartrate; Glaucoma; Humans; Intraocular Pressure; Quinoxalines | 2019 |
Brimonidine enhances inhibitory postsynaptic activity of OFF- and ON-type retinal ganglion cells in a Wistar rat chronic glaucoma model.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Brimonidine Tartrate; Chronic Disease; Disease Models, Animal; Excitatory Postsynaptic Potentials; Glaucoma; Intraocular Pressure; Male; Membrane Potentials; Patch-Clamp Techniques; Presynaptic Terminals; Rats; Rats, Wistar; Retinal Ganglion Cells; Synaptic Transmission | 2019 |
Ocular and systemic pharmacokinetics of brimonidine and brinzolamide after topical administration in rabbits: comparison between fixed-combination and single-drug formulations.
Topics: Administration, Topical; Adrenergic alpha-2 Receptor Agonists; Animals; Aqueous Humor; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Chromatography, High Pressure Liquid; Disease Models, Animal; Drug Compounding; Drug Therapy, Combination; Glaucoma; Male; Ophthalmic Solutions; Rabbits; Sulfonamides; Tandem Mass Spectrometry; Thiazines; Vitreous Body | 2021 |
Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model.
Topics: Animals; Brimonidine Tartrate; Follow-Up Studies; Glaucoma; Neuroprotective Agents; Rats; Silicates | 2020 |
Periocular allergic contact dermatitis caused by brinzolamide.
Topics: Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Dermatitis, Allergic Contact; Drug Combinations; Facial Dermatoses; Female; Glaucoma; Humans; Middle Aged; Ophthalmic Solutions; Sulfonamides; Thiazines | 2021 |
Improved Treatment Options for Glaucoma with Brimonidine-Loaded Lipid DNA Nanoparticles.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Base Sequence; Brimonidine Tartrate; DNA; Drug Carriers; Drug Liberation; Female; Glaucoma; Hydrophobic and Hydrophilic Interactions; Intraocular Pressure; Mice, Inbred DBA; Micelles; Nanoparticles; Oligodeoxyribonucleotides; Rats | 2021 |
Optical Coherence Tomography Angiography Vessel Density Changes in Normal-tension Glaucoma Treated With Carteolol, Brimonidine, or Dorzolamide.
Topics: Angiography; Brimonidine Tartrate; Carteolol; Female; Fluorescein Angiography; Glaucoma; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Nerve Fibers; Retinal Ganglion Cells; Retinal Vessels; Retrospective Studies; Sulfonamides; Thiophenes; Tomography, Optical Coherence; Visual Fields | 2021 |
Brimonidine related acute follicular conjunctivitis: Onset time and clinical presentations, a long-term follow-up.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Conjunctivitis, Allergic; Drug Administration Schedule; Female; Follow-Up Studies; Glaucoma; Humans; Intraocular Pressure; Longitudinal Studies; Male; Middle Aged; Ophthalmic Solutions; Retrospective Studies | 2021 |
Evaluation of the anti-Acanthamoeba activity of two commercial eye drops commonly used to lower eye pressure.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Adrenergic alpha-2 Receptor Agonists; Adrenergic beta-Antagonists; Analysis of Variance; Apoptosis; Brimonidine Tartrate; Brimonidine Tartrate, Timolol Maleate Drug Combination; Glaucoma; Inhibitory Concentration 50; Intraocular Pressure; Membrane Potential, Mitochondrial; Ophthalmic Solutions; Timolol | 2017 |
Pure Glaucoma Drugs Are Toxic to Immortalized Human Corneal Epithelial Cells, but They Do Not Destabilize Lipid Membranes.
Topics: Antihypertensive Agents; Apoptosis; Brimonidine Tartrate; Cell Line; Cell Membrane; Cell Survival; Electrophoresis, Capillary; Epithelium, Corneal; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Liposomes; Membrane Lipids; Ocular Hypertension; Pilocarpine; Prostaglandins F, Synthetic; Sulfonamides; Thiazines; Timolol | 2017 |
Validated HPLC-DAD Method for the Simultaneous Determination of Six Selected Drugs Used in the Treatment of Glaucoma.
Topics: Acetazolamide; Antihypertensive Agents; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Chromatography, High Pressure Liquid; Glaucoma; Humans; Levobunolol; Sulfonamides; Thiophenes; Timolol | 2018 |
Severe Corneal Disorders Developed After Brimonidine Tartrate Ophthalmic Solution Use.
Topics: Aged; Antihypertensive Agents; Brimonidine Tartrate; Conjunctivitis; Corneal Neovascularization; Female; Glaucoma; Humans; Ophthalmic Solutions | 2017 |
Comparison of the neuroprotective effects of brimonidine tartrate and melatonin on retinal ganglion cells.
Topics: Animals; Antioxidants; Apoptosis; Brimonidine Tartrate; Disease Models, Animal; Glaucoma; Intraocular Pressure; Male; Melatonin; Neuroprotective Agents; Rats; Rats, Wistar; Retinal Ganglion Cells; Tonometry, Ocular | 2018 |
Formulation and ex vivo-in vivo evaluation of pH-triggered brimonidine tartrate in situ gel for the glaucoma treatment using application of 3
Topics: Acrylic Resins; Biological Availability; Brimonidine Tartrate; Cornea; Gels; Glaucoma; Intraocular Pressure; Ophthalmic Solutions; Polymers; Viscosity | 2018 |
The More, the Better? The Usefulness of Brimonidine as the Fourth Antiglaucoma Eye Drop.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Cohort Studies; Drug Therapy, Combination; Female; Glaucoma; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Registries; Retrospective Studies; Sweden; Tonometry, Ocular | 2018 |
Amino-Functionalized Mesoporous Silica Particles for Ocular Delivery of Brimonidine.
Topics: Administration, Ophthalmic; Animals; Antihypertensive Agents; Aqueous Humor; Biological Availability; Brimonidine Tartrate; Drug Carriers; Drug Compounding; Drug Liberation; Glaucoma; Intraocular Pressure; Male; Models, Animal; Ophthalmic Solutions; Porosity; Rabbits; Silicon Dioxide | 2018 |
Impact of Ocular Compatible Lipoids and Castor Oil in Fabrication of Brimonidine Tartrate Nanoemulsions by 3
Topics: Administration, Ophthalmic; Biological Availability; Brimonidine Tartrate; Castor Oil; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Carriers; Glaucoma; Glycine max; Humans; Nanostructures; Patents as Topic; Phospholipids | 2018 |
A case of latanoprost-induced diffuse facial skin hyperpigmentation.
Topics: Administration, Cutaneous; Administration, Ophthalmic; Aged; Antihypertensive Agents; Biopsy; Brimonidine Tartrate; Dermatologic Agents; Drug Substitution; Face; Female; Glaucoma; Humans; Hyperpigmentation; Lasers, Solid-State; Latanoprost; Low-Level Light Therapy; Ophthalmic Solutions; Skin; Skin Pigmentation; Treatment Outcome | 2019 |
Effect of Ultra-Small Chitosan Nanoparticles Doped with Brimonidine on the Ultra-Structure of the Trabecular Meshwork of Glaucoma Patients.
Topics: Adrenergic alpha-2 Receptor Agonists; Brimonidine Tartrate; Chitosan; Drug Carriers; Glaucoma; Humans; Models, Theoretical; Nanocomposites; Trabecular Meshwork; Treatment Outcome | 2019 |
A versatile HPLC method with an isocratic single mobile phase system for simultaneous determination of anti-glaucoma formulations containing timolol.
Topics: Adrenergic beta-Antagonists; Brimonidine Tartrate; Chromatography, High Pressure Liquid; Drug Combinations; Drug Compounding; Glaucoma; Limit of Detection; Ophthalmic Solutions; Reference Standards; Reproducibility of Results; Sulfonamides; Thiazines; Thiophenes; Timolol | 2019 |
Proniosomal gel-derived niosomes: an approach to sustain and improve the ocular delivery of brimonidine tartrate; formulation, in-vitro characterization, and in-vivo pharmacodynamic study.
Topics: Animals; Brimonidine Tartrate; Drug Compounding; Drug Delivery Systems; Eye; Gels; Glaucoma; Intraocular Pressure; Liposomes; Male; Particle Size; Rabbits; Surface Properties | 2019 |
[Selective α2-agonists in the treatment of glaucoma: pharmacology, efficacy and safety].
Topics: Adrenergic alpha-Agonists; Brimonidine Tartrate; Glaucoma; Humans; Intraocular Pressure; Ophthalmic Solutions; Quinoxalines | 2019 |
Histopathologic Analysis of Conjunctival Lymphoproliferative Disease After Topical Brimonidine Use.
Topics: Administration, Topical; Aged; Aged, 80 and over; Brimonidine Tartrate; Conjunctiva; Female; Glaucoma; Humans; Lymphoproliferative Disorders; Male; Medical Records; Middle Aged; Retrospective Studies | 2019 |
Novel topical ophthalmic formulations for management of glaucoma.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Brimonidine Tartrate; Glaucoma; Lactic Acid; Mice; Nanoparticles; Ophthalmic Solutions; Polyesters; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Quinoxalines | 2013 |
Brinzolamide/brimonidine (Simbrinza) for glaucoma.
Topics: Administration, Ophthalmic; Adrenergic alpha-2 Receptor Agonists; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Drug Combinations; Glaucoma; Humans; Quinoxalines; Sulfonamides; Thiazines | 2013 |
Can ophthalmic drops cause central nervous system depression and cardiogenic shock in infants?
Topics: Absorption; Administration, Ophthalmic; Apnea; Bradycardia; Brimonidine Tartrate; Consciousness Disorders; Dose-Response Relationship, Drug; Drug Combinations; Emergencies; Female; Glaucoma; Humans; Hypothermia; Infant; Muscle Hypotonia; Nasal Mucosa; Ophthalmic Solutions; Quinoxalines; Shock, Cardiogenic; Sulfonamides; Thiazines; Timolol | 2013 |
[Current trend of glaucoma medication with various eye drops].
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Betaxolol; Brimonidine Tartrate; Glaucoma; Humans; Latanoprost; Neuroprotective Agents; Ophthalmic Solutions; Ophthalmology; Prostaglandins; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiophenes | 2013 |
Mechanism - based translational pharmacokinetic - pharmacodynamic model to predict intraocular pressure lowering effect of drugs in patients with glaucoma or ocular hypertension.
Topics: Animals; Antihypertensive Agents; Brimonidine Tartrate; Dogs; Female; Forecasting; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Male; Models, Biological; Ocular Hypertension; Prostaglandins F, Synthetic; Quinoxalines; Rabbits; Translational Research, Biomedical; Treatment Outcome | 2014 |
Transactivation of EGF receptors in chicken Müller cells by α2A-adrenergic receptors stimulated by brimonidine.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Blotting, Western; Brimonidine Tartrate; Cells, Cultured; Chick Embryo; Ependymoglial Cells; ErbB Receptors; Glaucoma; Immunohistochemistry; MAP Kinase Signaling System; Quinoxalines; Real-Time Polymerase Chain Reaction; Receptors, Adrenergic, alpha-2; Retina; RNA; Transcriptional Activation | 2014 |
Brimonidine prevents neurodegeneration in a mouse model of normal tension glaucoma.
Topics: Animals; Brimonidine Tartrate; Excitatory Amino Acid Transporter 3; Female; Glaucoma; Humans; Male; Mice; Mice, Knockout; Protective Agents; Quinoxalines; Receptors, N-Methyl-D-Aspartate; Retinal Degeneration; Retinal Ganglion Cells | 2014 |
Diadenosine tetraphosphate improves adrenergic anti-glaucomatous drug delivery and efficiency.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Aqueous Humor; Blotting, Western; Brimonidine Tartrate; Cell Membrane Permeability; Cells, Cultured; Dinucleoside Phosphates; Drug Delivery Systems; Electric Impedance; Epithelium, Corneal; Glaucoma; Humans; Intraocular Pressure; Male; Occludin; Quinoxalines; Rabbits; Tight Junctions; Timolol; Zonula Occludens-1 Protein | 2015 |
α2-Adrenergic modulation of the glutamate receptor and transporter function in a chronic ocular hypertension model.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Biological Transport; Brimonidine Tartrate; Chronic Disease; Excitatory Amino Acid Transporter 1; Glaucoma; Glial Fibrillary Acidic Protein; Glutamic Acid; Intraocular Pressure; Male; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Receptors, Glutamate | 2015 |
Mucoadhesive microparticles with a nanostructured surface for enhanced bioavailability of glaucoma drug.
Topics: Adhesiveness; Administration, Ophthalmic; Adrenergic alpha-2 Receptor Agonists; Animals; Aqueous Humor; Biological Availability; Brimonidine Tartrate; Drug Carriers; Drug Compounding; Glaucoma; Male; Mucus; Nanoparticles; Nanotechnology; Ophthalmic Solutions; Polyethylene Glycols; Polyglactin 910; Rabbits; Solubility; Technology, Pharmaceutical | 2015 |
Sustained reduction of intraocular pressure by supraciliary delivery of brimonidine-loaded poly(lactic acid) microspheres for the treatment of glaucoma.
Topics: Animals; Anterior Eye Segment; Antihypertensive Agents; Brimonidine Tartrate; Delayed-Action Preparations; Drug Delivery Systems; Glaucoma; Injections; Intraocular Pressure; Microspheres; Needles; Polyesters; Rabbits | 2016 |
Determination of phosphate concentration in glaucoma eye drops commercially available in Spain.
Topics: Brimonidine Tartrate; Buffers; Drugs, Generic; Glaucoma; Humans; Hydrogen-Ion Concentration; Latanoprost; Ophthalmic Solutions; Phosphates; Preservatives, Pharmaceutical; Prostaglandins F, Synthetic; Spain; Spectrophotometry, Ultraviolet; Timolol | 2016 |
Drugs, Inflammation, and the Eye.
Topics: Adrenergic alpha-2 Receptor Agonists; Antibodies, Monoclonal; Brimonidine Tartrate; Diphosphonates; Glaucoma; Humans; Ipilimumab; Orbital Cellulitis; Pharmaceutical Preparations; Uveitis, Anterior | 2016 |
Thermosensitive hexanoyl glycol chitosan-based ocular delivery system for glaucoma therapy.
Topics: Administration, Ophthalmic; Animals; Brimonidine Tartrate; Delayed-Action Preparations; Glaucoma; Glycols; Hot Temperature; Male; Rabbits | 2016 |
[Iritis : What has glaucoma to do with it?]
Topics: Aged, 80 and over; Anti-Inflammatory Agents; Antihypertensive Agents; Brimonidine Tartrate; Diagnosis, Differential; Female; Glaucoma; Humans; Iritis; Treatment Outcome | 2017 |
Long-Term Subconjunctival Delivery of Brimonidine Tartrate for Glaucoma Treatment Using a Microspheres/Carrier System.
Topics: Animals; Brimonidine Tartrate; Drug Delivery Systems; Glaucoma; Intraocular Pressure; Male; Microspheres; Polyesters; Rabbits | 2016 |
The Relationship of Brimonidine Concentration in Vitreous Body to the Free Concentration in Retina/Choroid Following Topical Administration in Pigmented Rabbits.
Topics: Administration, Topical; Animals; Antihypertensive Agents; Brimonidine Tartrate; Chromatography, Liquid; Disease Models, Animal; Glaucoma; Male; Melanins; Ophthalmic Solutions; Rabbits; Retina; Tandem Mass Spectrometry; Vitreous Body | 2017 |
Sustained Release of Brimonidine from a New Composite Drug Delivery System for Treatment of Glaucoma.
Topics: Brimonidine Tartrate; Delayed-Action Preparations; Drug Delivery Systems; Glaucoma; Humans; Polyethylene Glycols | 2017 |
Alpha2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Calcium; Calcium Signaling; Disease Models, Animal; Excitatory Amino Acid Agonists; Glaucoma; Male; N-Methylaspartate; Neuroprotective Agents; Patch-Clamp Techniques; Phosphodiesterase Inhibitors; Quinoxalines; Rabbits; Rats; Rats, Inbred BN; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Receptors, N-Methyl-D-Aspartate; Retina; Retinal Ganglion Cells; Rolipram | 2008 |
A medical device/drug delivery system for treatment of glaucoma.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Brimonidine Tartrate; Chromatography, High Pressure Liquid; Contact Lenses; Drug Delivery Systems; Female; Glaucoma; Humans; Hydrogel, Polyethylene Glycol Dimethacrylate; Intraocular Pressure; Male; Middle Aged; Quinoxalines; Timolol | 2009 |
Bilateral granulomatous uveitis as a side effect of topical brimonidine: two case reports.
Topics: Administration, Topical; Aged; Aged, 80 and over; Brimonidine Tartrate; Female; Glaucoma; Granuloma; Humans; Ophthalmic Solutions; Quinoxalines; Uveitis | 2009 |
Reaction of Müller cells in an experimental rat model of increased intraocular pressure following timolol, latanoprost and brimonidine.
Topics: Animals; Antihypertensive Agents; Brimonidine Tartrate; Disease Models, Animal; Glaucoma; Glial Fibrillary Acidic Protein; Gliosis; Intraocular Pressure; Latanoprost; Male; Neuroglia; Prostaglandins F, Synthetic; Quinoxalines; Rats; Rats, Wistar; Retina; Timolol; Tonometry, Ocular | 2010 |
Use of rituximab for periocular and intraocular mucosa-associated lymphoid tissue lymphoma.
Topics: Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Brimonidine Tartrate; Drug Therapy, Combination; Eye Neoplasms; Female; Glaucoma; Humans; Latanoprost; Loteprednol Etabonate; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Parotid Neoplasms; Prostaglandins F, Synthetic; Quinoxalines; Rituximab; Sulfonamides; Thiophenes; Timolol | 2010 |
Alpha2-adrenergic receptors and their core involvement in the process of axonal growth in retinal explants.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Autoradiography; Axons; Brimonidine Tartrate; Clonidine; Disease Models, Animal; Electrophoresis, Gel, Two-Dimensional; Fluorescent Antibody Technique, Indirect; Glaucoma; Glial Fibrillary Acidic Protein; Optic Nerve Injuries; Organ Culture Techniques; Platelet Activating Factor; Protein Disulfide-Isomerases; Proteomics; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Receptors, Laminin; Retina; Retinal Degeneration; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2010 |
Brimonidine hypersensitivity when switching between 0.2% and 0.15% formulations.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Aged; Aged, 80 and over; Brimonidine Tartrate; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Hypersensitivity; Eye; Female; Glaucoma; Humans; Intraocular Pressure; Male; Middle Aged; Ophthalmic Solutions; Quinoxalines; Treatment Outcome | 2010 |
The clinical impact of 2 different strategies for initiating therapy in patients with ocular hypertension.
Topics: Adult; Antihypertensive Agents; Blindness; Brimonidine Tartrate; Decision Trees; Disease Progression; Drug Therapy, Combination; Female; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Male; Markov Chains; Middle Aged; Models, Biological; Monte Carlo Method; Ocular Hypertension; Prostaglandins F, Synthetic; Quinoxalines; Risk Assessment; Sulfonamides; Thiophenes; Timolol | 2011 |
Persistence of glaucoma medical therapy in the Glasgow Glaucoma Database.
Topics: Algorithms; Antihypertensive Agents; Betaxolol; Brimonidine Tartrate; Clinical Protocols; Databases, Factual; Drug Utilization; Female; Glaucoma; Humans; Male; Ocular Hypertension; Quinoxalines; Scotland; Timolol | 2011 |
Ocular perforation by an acupuncture needle.
Topics: Acupuncture Therapy; Aged; Antihypertensive Agents; Brimonidine Tartrate; Combined Modality Therapy; Eye Injuries, Penetrating; Glaucoma; Humans; Laser Coagulation; Male; Needles; Needlestick Injuries; Quinoxalines; Retina; Retinal Perforations; Timolol; Visual Acuity; Vitrectomy; Vitreous Hemorrhage | 2011 |
Nanovesicular formulation of brimonidine tartrate for the management of glaucoma: in vitro and in vivo evaluation.
Topics: Animals; Brimonidine Tartrate; Chemistry, Pharmaceutical; Cornea; Disease Management; Drug Carriers; Glaucoma; Nanoparticles; Quinoxalines; Rabbits | 2011 |
Brimonidine tartrate-eudragit long-acting nanoparticles: formulation, optimization, in vitro and in vivo evaluation.
Topics: Acrylic Resins; Administration, Ophthalmic; Adrenergic alpha-2 Receptor Agonists; Animals; Brimonidine Tartrate; Chemistry, Pharmaceutical; Delayed-Action Preparations; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Drug Stability; Glaucoma; Hydrogen-Ion Concentration; Intraocular Pressure; Kinetics; Nanoparticles; Nanotechnology; Quinoxalines; Rabbits; Solubility; Technology, Pharmaceutical | 2011 |
[Pupillary block acute glaucoma due to acrylic intraocular lens posterior dislocation after Nd:YAG capsulotomy].
Topics: Acute Disease; Aged; Brimonidine Tartrate; Combined Modality Therapy; Dipyrone; Drug Therapy, Combination; Emergencies; Female; Furosemide; Glaucoma; Hernia; Humans; Iris; Laser Therapy; Lasers, Solid-State; Lens Capsule, Crystalline; Lens Subluxation; Lenses, Intraocular; Mannitol; Metoclopramide; Postoperative Complications; Pseudophakia; Pupil Disorders; Quinoxalines; Timolol; Vitrectomy; Vitreous Body | 2011 |
Polyamidoamine dendrimer hydrogel for enhanced delivery of antiglaucoma drugs.
Topics: Animals; Brimonidine Tartrate; Cattle; Cell Line; Dendrimers; Drug Combinations; Drug Delivery Systems; Epithelium, Corneal; Glaucoma; Humans; Hydrogel, Polyethylene Glycol Dimethacrylate; Ophthalmic Solutions; Quinoxalines; Timolol | 2012 |
Biodegradable ocular inserts for sustained delivery of brimonidine tartarate: preparation and in vitro/in vivo evaluation.
Topics: Absorbable Implants; Acrylic Resins; Administration, Ophthalmic; Adrenergic alpha-2 Receptor Agonists; Alginates; Animals; Brimonidine Tartrate; Calorimetry, Differential Scanning; Cellulose; Chemistry, Pharmaceutical; Chitosan; Delayed-Action Preparations; Disease Models, Animal; Drug Carriers; Drug Compounding; Glaucoma; Glucuronic Acid; Hexuronic Acids; Hydrophobic and Hydrophilic Interactions; Hypromellose Derivatives; Intraocular Pressure; Kinetics; Methylcellulose; Ophthalmic Solutions; Polymers; Polymethacrylic Acids; Polyvinyls; Povidone; Quinoxalines; Rabbits; Solubility; Spectroscopy, Fourier Transform Infrared; Technology, Pharmaceutical; X-Ray Diffraction | 2011 |
Sustained ocular delivery of brimonidine tartrate using ion activated in situ gelling system.
Topics: Animals; Biological Availability; Brimonidine Tartrate; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Delivery Systems; Drug Stability; Eye; Gels; Glaucoma; Hydrogen-Ion Concentration; Ions; Ophthalmic Solutions; Polysaccharides, Bacterial; Quinoxalines; Rabbits | 2012 |
The activity of lowering intraocular pressure of cassiae seed extract in a DBA/2J mouse glaucoma model.
Topics: Acetazolamide; Animals; Antihypertensive Agents; Aqueous Humor; Brimonidine Tartrate; Cassia; Chromatography, High Pressure Liquid; Disease Models, Animal; Glaucoma; Glycosides; Intraocular Pressure; L-Lactate Dehydrogenase; Male; Mice; Mice, Inbred DBA; Plant Extracts; Polyphenols; Quinoxalines; Seeds | 2013 |
[Pharmacological profile and clinical efficacy of brimonidine tartrate (AIPHAGAN(®) ophthalmic solution 0.1%)].
Topics: Adrenergic alpha-2 Receptor Agonists; Brimonidine Tartrate; Clinical Trials as Topic; Glaucoma; Humans; Intraocular Pressure; Ophthalmic Solutions; Quinoxalines | 2012 |
[Use of glaucoma medications during pregnancy and breastfeeding].
Topics: Abnormalities, Drug-Induced; Administration, Ophthalmic; Administration, Oral; Adrenergic beta-Antagonists; Animals; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Contraindications; Female; Fetus; Gels; Glaucoma; Humans; Hypotension; Intraocular Pressure; Lactation; Obstetric Labor, Premature; Ophthalmic Solutions; Pregnancy; Pregnancy Complications; Prostaglandins; Quinoxalines; Timolol | 2012 |
Brimonidine-timolol fixed combination induced granulomatous inflammation of the eye.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Conjunctivitis; Drug Therapy, Combination; Female; Glaucoma; Humans; Male; Middle Aged; Quinoxalines; Timolol; Uveitis | 2013 |
Discontinuation rates of topical glaucoma medications in a managed care population.
Topics: Administration, Topical; Adult; Antihypertensive Agents; Brimonidine Tartrate; Chi-Square Distribution; Female; Glaucoma; Humans; Latanoprost; Male; Middle Aged; Ophthalmic Solutions; Patient Compliance; Proportional Hazards Models; Prostaglandins F, Synthetic; Quinoxalines; Retrospective Studies; Survival Analysis; Timolol | 2002 |
Effects of anti-glaucoma medications on ganglion cell survival: the DBA/2J mouse model.
Topics: Aging; Analysis of Variance; Animals; Antihypertensive Agents; Brimonidine Tartrate; Cell Survival; Disease Models, Animal; Glaucoma; Memantine; Mice; Mice, Inbred DBA; Quinoxalines; Retinal Ganglion Cells; Timolol | 2002 |
[Increased myopia and metaporphosia in a 59-year old patient. Serous retinal detachment of the posterior pol after latanoprost administration].
Topics: Antihypertensive Agents; Blood-Retinal Barrier; Brimonidine Tartrate; Diagnosis, Differential; Drug Therapy, Combination; Fluorescein Angiography; Glaucoma; Humans; Latanoprost; Male; Middle Aged; Myopia; Prostaglandins F, Synthetic; Quinoxalines; Retinal Detachment; Visual Acuity | 2003 |
Cystoid macular oedema associated with brimonidine therapy.
Topics: Aged; Antihypertensive Agents; Brimonidine Tartrate; Female; Fluorescein Angiography; Glaucoma; Humans; Macular Edema; Quinoxalines | 2003 |
Hypotension and bradycardia in infants after the use of topical brimonidine and beta-blockers.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Bradycardia; Brimonidine Tartrate; Female; Glaucoma; Humans; Hypotension; Infant; Infant, Newborn; Intraocular Pressure; Quinoxalines | 2003 |
Effects of commercial antiglaucoma drugs to glutamate-induced [Ca2+)]i increase in cultured neuroblastoma cells.
Topics: Animals; Antihypertensive Agents; Betaxolol; Brimonidine Tartrate; Calcium; Carteolol; Cell Death; Dose-Response Relationship, Drug; Epinephrine; Glaucoma; Glutamic Acid; Latanoprost; Mice; Neuroblastoma; Neurons; Neuroprotective Agents; Pilocarpine; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiazines; Thiophenes; Timolol; Tumor Cells, Cultured | 2003 |
Patient persistency with pharmacotherapy in the management of glaucoma.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Brimonidine Tartrate; Cohort Studies; Drug Utilization; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Middle Aged; Ocular Hypertension; Patient Compliance; Prostaglandins F, Synthetic; Quinoxalines; Retrospective Studies; Sulfonamides; Thiophenes | 2003 |
Prescription of topical antiglaucoma agents for patients with contraindications to beta-blockers.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Betaxolol; Brimonidine Tartrate; Contraindications; Databases, Factual; Drug Prescriptions; Female; Glaucoma; Humans; Latanoprost; Male; Middle Aged; National Health Programs; Ophthalmic Solutions; Prostaglandins F, Synthetic; Quebec; Quinoxalines; Retrospective Studies; Sulfonamides; Thiophenes; Timolol | 2003 |
Ocular and systemic side effects of brimonidine 0.2% eye drops (Alphagan) in children.
Topics: Adolescent; Adrenergic alpha-Agonists; Antihypertensive Agents; Brimonidine Tartrate; Child; Child, Preschool; Eye Diseases; Female; Glaucoma; Humans; Infant; Infant, Newborn; Male; Ophthalmic Solutions; Quinoxalines; Sleep Stages; Syncope | 2004 |
Demographic and clinical factors associated with development of brimonidine tartrate 0.2%-induced ocular allergy.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Conjunctivitis, Allergic; Demography; Dermatitis, Allergic Contact; Drug Hypersensitivity; Eyelid Diseases; Female; Glaucoma; Humans; Male; Middle Aged; Ophthalmic Solutions; Quinoxalines; Retrospective Studies; Risk Factors | 2004 |
Anterior uveitis and concurrent allergic conjunctivitis associated with long-term use of topical 0.2% brimonidine tartrate.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Conjunctivitis, Allergic; Female; Glaucoma; Glucocorticoids; Humans; Intraocular Pressure; Male; Ophthalmic Solutions; Prednisolone; Quinoxalines; Uveitis, Anterior | 2004 |
Alphagan allergy may increase the propensity for multiple eye-drop allergy.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Cross Reactions; Drug Administration Schedule; Drug Hypersensitivity; Female; Glaucoma; Glaucoma, Open-Angle; Humans; Longitudinal Studies; Male; Middle Aged; Ophthalmic Solutions; Quinoxalines; Retrospective Studies; Sulfonamides; Thiophenes; Timolol | 2005 |
Prospective survey of adverse reactions to topical antiglaucoma medications in a hospital population.
Topics: Adrenergic alpha-Agonists; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Female; Filtering Surgery; Glaucoma; Humans; Intraocular Pressure; Male; Middle Aged; Ophthalmic Solutions; Outpatient Clinics, Hospital; Patient Acceptance of Health Care; Prospective Studies; Quinoxalines; Time Factors | 2005 |
[Neuroprotection and vasoprotection in glaucoma].
Topics: Antihypertensive Agents; Betaxolol; Brimonidine Tartrate; Carteolol; Drug Therapy, Combination; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Neuroprotective Agents; Ophthalmic Solutions; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiophenes; Treatment Outcome | 2004 |
Cost considerations of the new fixed combinations for glaucoma medical therapy.
Topics: Administration, Topical; Antihypertensive Agents; Brimonidine Tartrate; Canada; Drug Combinations; Glaucoma; Humans; Latanoprost; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiophenes; Timolol | 2005 |
Side-effect profile of brimonidine tartrate in children.
Topics: Adolescent; Adrenergic alpha-Agonists; Brimonidine Tartrate; Central Nervous System Diseases; Child; Child, Preschool; Female; Glaucoma; Humans; Infant; Intraocular Pressure; Male; Prospective Studies; Quinoxalines; Risk Factors; Sleep; Sleep Stages; Surveys and Questionnaires | 2005 |
Argon laser trabeculoplasty and reduction of ocular hypotensive medication used by glaucoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Chronic Disease; Circadian Rhythm; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glaucoma; Humans; Intraocular Pressure; Laser Therapy; Male; Middle Aged; Quinoxalines; Trabeculectomy; Treatment Outcome | 2006 |
[Ocular hypertension in children treated with brimonidine 0.2%. A clinical study].
Topics: Administration, Topical; Antihypertensive Agents; Brimonidine Tartrate; Child; Female; Glaucoma; Humans; Intraocular Pressure; Male; Ocular Hypertension; Quinoxalines; Retrospective Studies; Treatment Outcome | 2006 |
Is brimonidine ophthalmic a safe therapy for infants?
Topics: Adrenergic alpha-Agonists; Bradycardia; Brimonidine Tartrate; Glaucoma; Humans; Hypotension; Infant; Male; Ophthalmic Solutions; Quinoxalines | 2006 |
[Intraocular pressure after ND: YAG laser capsulotomy in pseudophakic patients with glaucoma].
Topics: Administration, Topical; Antihypertensive Agents; Brimonidine Tartrate; Cataract Extraction; Glaucoma; Humans; Intraocular Pressure; Laser Therapy; Lens Capsule, Crystalline; Preoperative Care; Pseudophakia; Quinoxalines; Sulfonamides; Thiophenes | 2006 |
Measurement of inflammatory cytokines by multicytokine assay in tears of patients with glaucoma topically treated with chronic drugs.
Topics: Administration, Topical; Aged; Amides; Antihypertensive Agents; Bimatoprost; Brimonidine Tartrate; Carteolol; Case-Control Studies; Chemokines; Cloprostenol; Cytokines; Dose-Response Relationship, Immunologic; Drug Therapy, Combination; Female; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Lipids; Male; Prospective Studies; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Tears; Thiophenes; Timolol | 2007 |
Brimonidine/Timolol: a viewpoint by Richard Fiscella.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Drug Therapy, Combination; Glaucoma; Humans; Intraocular Pressure; Quinoxalines; Randomized Controlled Trials as Topic; Timolol; Treatment Outcome | 2006 |
Brimonidine/Timolol: a viewpoint by Robert M. Feldman.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Drug Therapy, Combination; Glaucoma; Humans; Prostaglandins F, Synthetic; Quinoxalines; Timolol | 2006 |
Brimonidine/Timolol: a viewpoint by Francisco J. Goñi.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Drug Therapy, Combination; Glaucoma; Humans; Intraocular Pressure; Ocular Hypertension; Quinoxalines; Randomized Controlled Trials as Topic; Sulfonamides; Thiophenes; Timolol; Treatment Outcome | 2006 |
[Depression of respiration via toxic effects on the central nervous system following use of topical brimonidine in an infant with congenital glaucoma].
Topics: Antihypertensive Agents; Apnea; Brimonidine Tartrate; Cataract; Female; Glaucoma; Humans; Infant, Newborn; Infant, Premature, Diseases; Neurotoxicity Syndromes; Ophthalmic Solutions; Postoperative Complications; Quinoxalines; Respiratory Insufficiency; Trabeculectomy | 2007 |
New drug information. Combigan.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Glaucoma; Humans; Intraocular Pressure; Quinoxalines; Timolol | 2008 |
New agents for the treatment of glaucoma.
Topics: Adrenergic alpha-Agonists; Brimonidine Tartrate; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Prostaglandins F, Synthetic; Quinoxalines | 1997 |
Brimonidine--an alpha 2-agonist for glaucoma.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Brimonidine Tartrate; Clinical Trials as Topic; Contraindications; Glaucoma; Humans; Intraocular Pressure; Quinoxalines; Xerostomia | 1997 |
Update in glaucoma: the new pharmacotherapies. Brimonidine versus apraclonidine.
Topics: Adrenergic alpha-Agonists; Antihypertensive Agents; Brimonidine Tartrate; Clonidine; Glaucoma; Humans; Quinoxalines | 1998 |
[Modern anti-glaucoma drugs and their secondary effects].
Topics: Adrenergic alpha-Agonists; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Dinoprost; Glaucoma; Humans; Quinoxalines; Sulfonamides; Thiophenes | 1998 |
The effect of latanoprost and brimonidine on rabbit subconjunctival fibroblasts.
Topics: Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Cell Count; Cell Division; Conjunctiva; Disease Models, Animal; Fibroblasts; Glaucoma; Intraocular Pressure; Latanoprost; Microfilament Proteins; Ophthalmic Solutions; Proliferating Cell Nuclear Antigen; Prostaglandins F, Synthetic; Quinoxalines; Rabbits | 1999 |
[Four new drugs for glaucoma: apraclonidine, brimonidine, dorzolamide and latanoprost].
Topics: Adrenergic alpha-Agonists; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Clonidine; Drug Approval; Female; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Male; Netherlands; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiophenes | 1999 |
Systemic adverse effects of topical treatment with brimonidine in an infant with secondary glaucoma.
Topics: Adrenergic alpha-Agonists; Blood-Brain Barrier; Brimonidine Tartrate; Central Nervous System; Glaucoma; Humans; Infant; Quinoxalines | 1999 |
Apparent central nervous system depression in infants after the use of topical brimonidine.
Topics: Adrenergic alpha-Agonists; Brimonidine Tartrate; Central Nervous System; Follow-Up Studies; Glaucoma; Humans; Infant; Infant, Newborn; Intraocular Pressure; Male; Nervous System Diseases; Ocular Hypertension; Ophthalmic Solutions; Quinoxalines | 1999 |
Demonstration of the reversibility of optic disc topography by scanning laser ophthalmoscopy.
Topics: Adrenergic alpha-Agonists; Aniridia; Brimonidine Tartrate; Child; Drug Therapy, Combination; Glaucoma; Humans; Intraocular Pressure; Lasers; Latanoprost; Male; Ophthalmoscopy; Optic Disk; Optic Nerve Diseases; Prostaglandins F, Synthetic; Quinoxalines; Trabeculectomy; Visual Acuity | 1999 |
Incidence of brimonidine allergy in patients previously allergic to apraclonidine.
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Brimonidine Tartrate; Clonidine; Conjunctivitis; Cross Reactions; Dermatitis, Allergic Contact; Drug Hypersensitivity; Female; Glaucoma; Humans; Hyperemia; Incidence; Male; Middle Aged; Quinoxalines; Retrospective Studies; Risk Factors | 2000 |
Anterior uveitis as a side effect of topical brimonidine.
Topics: Acute Disease; Administration, Topical; Adrenergic alpha-Agonists; Aged; Aged, 80 and over; Anterior Eye Segment; Brimonidine Tartrate; Female; Glaucoma; Humans; Intraocular Pressure; Male; Ophthalmic Solutions; Quinoxalines; Recurrence; Uveitis, Anterior; Visual Acuity | 2000 |
Comparison of the ocular hypotensive effect of brimonidine, dorzolamide, latanoprost, or artificial tears added to timolol in glaucomatous monkey eyes.
Topics: Animals; Antihypertensive Agents; Brimonidine Tartrate; Drug Synergism; Drug Therapy, Combination; Female; Glaucoma; Intraocular Pressure; Latanoprost; Macaca fascicularis; Ophthalmic Solutions; Prostaglandins F, Synthetic; Quinoxalines; Random Allocation; Sulfonamides; Thiophenes; Timolol | 2000 |
[Neuroprotection. Bases and possibilities of a future clinical use].
Topics: Adrenergic alpha-Agonists; Animals; Apoptosis; Brimonidine Tartrate; Clinical Trials as Topic; Disease Models, Animal; Dopamine Agents; Eye Diseases; Forecasting; Glaucoma; Humans; Memantine; Neuroprotective Agents; Optic Neuritis; Quinoxalines; Retinal Diseases; Visual Fields | 2001 |
Quantitation of mitomycin C in human ocular tissues by high-performance liquid chromatography-photo-diode array detection.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Chromatography, High Pressure Liquid; Glaucoma; Humans; Mitomycin; Molecular Structure; Premedication; Quinoxalines; Sclera; Timolol; Trabeculectomy | 2001 |
Neuroprotective effect of alpha(2) agonist (brimonidine) on adult rat retinal ganglion cells after increased intraocular pressure.
Topics: Adrenergic alpha-Antagonists; Age Factors; Animals; Brimonidine Tartrate; Cell Count; Cell Survival; Disease Models, Animal; Female; Glaucoma; Intraocular Pressure; Nerve Degeneration; Neuroprotective Agents; Quinoxalines; Rats; Rats, Wistar; Retinal Ganglion Cells; Time Factors | 2001 |
[Experience with topical brimonidine in the treatment of glaucomas].
Topics: Antihypertensive Agents; Brimonidine Tartrate; Glaucoma; Humans; Quinoxalines | 2001 |
[Prospects for neuroprotective glaucoma therapy].
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Apoptosis; Betaxolol; Brain-Derived Neurotrophic Factor; Brimonidine Tartrate; Calcium Channel Blockers; Disease Models, Animal; Dopamine Agents; Glaucoma; Glaucoma, Open-Angle; Haplorhini; Humans; Memantine; Neuroprotective Agents; Nimodipine; Nitric Oxide Synthase; Quinoxalines; Receptors, N-Methyl-D-Aspartate | 2001 |
The impact of new drugs on management of glaucoma in Scotland: observational study.
Topics: Adrenergic alpha-Agonists; Antihypertensive Agents; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Drug Utilization; Glaucoma; Humans; Practice Patterns, Physicians'; Prostaglandins, Synthetic; Quinoxalines; Scotland; Trabeculectomy | 2001 |
Allergic reactions to brimonidine in patients treated for glaucoma.
Topics: Adrenergic alpha-Agonists; Aged; Antihypertensive Agents; Brimonidine Tartrate; Conjunctivitis, Allergic; Dermatitis, Allergic Contact; Drug Hypersensitivity; Female; Glaucoma; Humans; Levobunolol; Male; Quinoxalines; Retrospective Studies; Seasons | 2002 |
The effects of new topical treatments on management of glaucoma in Scotland: an examination of ophthalmological health care.
Topics: Administration, Topical; Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Drug Costs; Drug Prescriptions; Glaucoma; Humans; Latanoprost; Middle Aged; Miotics; Prostaglandins F, Synthetic; Prostaglandins, Synthetic; Quinoxalines; Retrospective Studies; Scotland; Sulfonamides; Sympathomimetics; Thiophenes; Trabeculectomy | 2002 |
Brimonidine 0.2% to prevent post laser IOP elevation.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Glaucoma; Humans; Intraocular Pressure; Iris; Laser Therapy; Ocular Hypertension; Postoperative Complications; Quinoxalines; Trabeculectomy | 2002 |
Additive intraocular pressure lowering effect of various medications with latanoprost.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Drug Synergism; Female; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Male; Prostaglandins F, Synthetic; Quinoxalines; Retrospective Studies; Sulfonamides; Thiophenes | 2002 |